Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week show that lenvatinib (Lenvima) plus everolimus (Afinitor) in kidney cancer significantly improved progression free survival (PFS) compared with everolimus or lenvatinib alone.
Patients with metastatic renal cell carcinoma (mRCC) treated with lenvatinib plus everolimus following one prior VEGF targeted therapy have significantly improved progression free survival (PFS) compared with everolimus or lenvatinib alone. The PFS advantage of lenvatinib plus everolimus vs everolimus alone remains following one prior VEGF targeted therapy, regardless of Memorial Sloan Kettering Cancer Center (MSKCC) risk group, baseline tumour size, or metastasis site. For the study secondary endpoint, updated median overall survival continues to trend towards improvement with lenvatinib plus everolimus (25.5 months compared to 19.1 month with lenvatinib alone and 15.4 months with everolimus alone).
Progression-free survival is significantly extended in people with mRCC for lenvatinib plus everolimus versus everolimus alone (14.6 versus 5.5 months).